Effect of menopausal symptom treatment options on palpitations: a systematic review

• Published in: Climacteric : the journal of the International Menopause Society 2022-03, Vol.25 (2), p.128-140
• Main Authors: Sheng, Y., Carpenter, J. S., Elomba, C. D., Alwine, J. S., Yue, M., Chen, C. X., Tisdale, J. E.
• Format: Article
• Language: English
• Subjects: Cognitive Behavioral Therapy; Female; Humans; Isoflavones; menopausal symptoms; Menopausal therapy; Menopause; palpitations; perimenopause; postmenopause; systematic review
• ISSN: 1369-7137; 1473-0804
• DOI: 10.1080/13697137.2021.1948006

This systematic review provides an overview of the effects of menopausal symptom treatment options on palpitations, defined as feelings of missed or exaggerated heart beats, reported by perimenopausal and postmenopausal women. Guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searches were conducted in PubMed, CINAHL and PsycINFO to identify articles meeting pre-specified inclusion criteria. Of 670 unique articles identified, 37 were included in the review. Treatments included drug therapies and non-drug therapies. Palpitations were studied as an outcome in 89% of articles and as an adverse effect in 11%. Articles provided mostly level II/III evidence due to their design and/or small sample sizes. Based on available evidence, no therapies can be fully recommended for clinical practice. Only some hormonal agents (e.g. estradiol) can be recommended with caution based on some positive evidence for reducing palpitation prevalence or severity. However, other drug therapies (e.g. moxonidine, atenolol), dietary supplementary treatments (e.g. isoflavones, Rheum rhaponticum, sage), cognitive-behavioral intervention and auricular acupressure cannot be recommended given the existing evidence. Additional well-designed randomized controlled treatment trials focusing on palpitations during the menopause transition as an inclusion criteria and outcome are needed to advance the field.